Our analysis combined the outcomes of 2,591 bladder cancer patients from 15 individual studies, indicating that altered cyclin D1 expression was not correlated with OS, RFS, and DFS of bladder cancer patients, but was with PFS (HR: 0.54, 95% CI: 0.32–0.92). The gene discussed is CCND1; the disease is urinary bladder carcinoma.